Acadia Pharmaceuticals Inc.
19.73USD
-0.5800 (-2.86%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ACAD.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.18▲ | $0.13 | 1 | 1 |
| Next quarter | $0.21▲ | $0.17 | 0 | 2 |
| Current year | $0.6▲ | $0.37 | 13 | 0 |
| Next year | $0.92▲ | $0.85 | 1 | 2 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.04 | $0.18 | +0.14 (+317.2%) |
| 2026-03-31 | $0.08 | $0.02 | -0.06 (-75.2%) |
| 2025-12-31 | $0.14 | $0.14 | -0.01 (-4.2%) |
| 2025-09-30 | $0.15 | $0.42 | +0.27 (+189.0%) |
342 ratings from 33 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Needham | Reiterated | Buy | $35 | Oct 19, 2026 |
| UBS | Downgraded from Buy | Neutral | $49 $23 | Oct 13, 2026 |
| RBC Capital | Maintained | Outperform | $37 $36 | Oct 8, 2026 |
| Deutsche Bank | Maintained | Buy | $38 $31 | Sep 25, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $37 $33 | Sep 25, 2026 |
| Citizens | Maintained | Market Outperform | $36 $33 | Sep 25, 2026 |
| BMO Capital | Maintained | Outperform | $36 $34 | Sep 25, 2026 |
| Needham | Maintained | Buy | $41 $35 | Sep 25, 2026 |
| Citigroup | Maintained | Buy | $40 $33 | Sep 24, 2026 |
| Needham | Reiterated | Buy | $41 | Sep 24, 2026 |
| Deutsche Bank | Maintained | Buy | $37 $38 | Aug 25, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $27 $28 | Aug 25, 2026 |
| Citigroup | Maintained | Buy | $39 $40 | Aug 25, 2026 |
| UBS | Maintained | Buy | $45 $49 | Aug 17, 2026 |
| Needham | Maintained | Buy | $38 $41 | Aug 12, 2026 |
| Citigroup | Maintained | Buy | $35 $39 | Aug 10, 2026 |
| Oppenheimer | Maintained | Perform | $23 $25 | Aug 5, 2026 |
| RBC Capital | Maintained | Outperform | $36 $37 | Aug 5, 2026 |
| Citizens | Maintained | Market Outperform | $35 $36 | Aug 5, 2026 |
| BMO Capital | Maintained | Outperform | $34 $36 | Jul 21, 2026 |
| Stifel | Maintained | Hold | $24 $25 | Jul 21, 2026 |
| RBC Capital | Maintained | Outperform | $29 $36 | Jul 7, 2026 |
| B of A Securities | Maintained | Buy | $29 $30 | Jun 30, 2026 |
| Citigroup | Maintained | Buy | $32 $35 | Jun 29, 2026 |
| Canaccord Genuity | Maintained | Buy | $32 $36 | Jun 29, 2026 |
76 filings from 15 insiders · 11 buy / 6 sell over 6m
Officers and directors of ACAD, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SCHNEYER MARK C.Chief Financial Officer | Exercise | 20.1k | $17.84 | $359k | Aug 6, 2026 |
| SCHNEYER MARK C.Chief Financial Officer | Sell | 20.1k | $29.00 | $587k | Aug 6, 2026 |
| THOMPSON ELIZABETH H.Z.Officer | Sell | 16.6k | $26.13 | $433k | Jul 30, 2026 |
| THOMPSON ELIZABETH H.Z.Officer | Other | 32.3k | — | — | Jul 29, 2026 |
| KIHARA JAMESOfficer | Sell | 11.4k | $26.08 | $298k | Jun 26, 2026 |
| BAKER BROS ADVISORS L.P.Beneficial Owner of more than 10% of a Class of Security | Grantindirect | 37.2k | — | — | May 29, 2026 |
| BREGE LAURA ADirector | Other | 8.1k | — | — | May 29, 2026 |
| POOLE JONATHANDirector | Other | 2.0k | — | — | May 29, 2026 |
| DALY JAMES M.Director | Other | 8.1k | — | — | May 29, 2026 |
| NDU ADORADirector | Other | 8.1k | — | — | May 29, 2026 |
| GAROFALO ELIZABETH AMY M.D.Director | Other | 8.1k | — | — | May 29, 2026 |
| HARRIGAN EDMUND P. M.D.Director | Other | 8.1k | — | — | May 29, 2026 |
| KIHARA JAMESOfficer | Sell | 5.4k | $21.18 | $114k | May 26, 2026 |
| KIHARA JAMESOfficer | Sell | 1.3k | $21.79 | $29k | May 4, 2026 |
| SCHNEYER MARK C.Chief Financial Officer | Sell | 3.5k | $21.79 | $76k | May 4, 2026 |
| KIHARA JAMESOfficer | Other | 2.6k | — | — | May 1, 2026 |
| SCHNEYER MARK C.Chief Financial Officer | Other | 6.8k | — | — | May 1, 2026 |
| KIHARA JAMESOfficer | Sell | 1.0k | $22.20 | $23k | Apr 7, 2026 |
| SCHNEYER MARK C.Chief Financial Officer | Sell | 2.7k | $22.20 | $60k | Apr 7, 2026 |
| KIHARA JAMESOfficer | Other | 2.0k | — | — | Apr 2, 2026 |
No analyst notes on ACAD yet.
Members whose judged calls on ACAD have played out most reliably.
No settled calls on ACAD yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice
Analyst Ratings
19 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 10 | 5 | 1 | 0 | Buy2.15 |
| 1 mo ago | 4 | 11 | 4 | 1 | 0 | Buy2.10 |
| 2 mo ago | 4 | 12 | 4 | 1 | 0 | Buy2.10 |
| 3 mo ago | 4 | 12 | 4 | 1 | 0 | Buy2.10 |